Author

I. Lagutina

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Research Focus:cell type annotation· 1 Research Focus:cell-cell communication· 1 Research Focus:clustering· 1 Research Focus:differential expression· 1 Organism:mouse· 1 Organism:plant (other)· 1

Frequent Co-Authors

A. Perota· 1 shared A. Salama· 1 shared A. Wandinger-Ness· 1 shared B. Vanhove· 1 shared C. Ciron· 1 shared C. Galli· 1 shared C. K. P. Mok· 1 shared D. Blanchard· 1 shared

Activity by Year

2020-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 29 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperImmunology

A. Perota

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Humanized NBSGW PDX Models of Disseminated Ovarian Cancer Recapitulate Key Aspects of the Tumor Immune Environment within the Peritoneal Cavity

M. P. Steinkamp, I. Lagutina, K. J. Brayer, F. Schultz, D. Burke, V. S. Pankratz, S. F. Adams, L. G. Hudson, S. A. Ness, A. Wandinger-Ness

This study develops humanized PDX models of ovarian cancer that replicate key immune features of the tumor microenvironment in the peritoneal cavity.

bioRxiv · Jul 1, 2022 · PreprintCancer Biology

High neutralizing potency of swine glyco-humanized polyclonal antibodies against SARS-CoV-2

B. Vanhove, O. Duvaux, J. Rousse, P.-J. Royer, G. Evanno, C. Ciron, E. Lheriteau, L. Vacher, N. Gervois, R. Oger, Y. Jacques, S. Conchon, A. Salama, R. Duchi, I. Lagutina, , J.-P. Soulillou

This paper describes the development of glyco-humanized swine polyclonal antibodies (GH-pAb) that neutralize SARS-CoV-2 with high potency and safety, and suggests clinical evaluation of the antibody XAV-19.

bioRxiv · Jul 25, 2020Immunology